Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of L-DOPA-induced dyskinesia

Neurobiology of Disease

Volumn 8, Issue 2, 2001, Pages 220-239

  Johansson, P A ^a   Andersson, M ^a   Andersson, K E ^a   Cenci, M A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Dynorphin; Enkephalin; In situ hybridization; Movement disorders; Neocortex; Neuropeptides; Parkinson's disease; Striatonigral; Striatopallidal

Indexed keywords

BENSERAZIDE; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; LEVODOPA; MESSENGER RNA; MU OPIATE RECEPTOR; NEUROPEPTIDE; OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTORADIOGRAPHY; BASAL GANGLION; BRAIN CORTEX; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DYSKINESIA; FEMALE; GLOBUS PALLIDUS; IN SITU HYBRIDIZATION; LIGAND BINDING; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT; STRIATE CORTEX;

EID: 0035036009     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.2000.0372     Document Type: Article

References (62)

1. The functional anatomy of basal ganglia disorders
2. Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa
3. Inhibitory actions of opioid compounds on calcium fluxes and neurotransmitter release from mammalian cerebral cortical slices
4. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease
5. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin and glutamic acid decarboxylase mRNA
6. Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): A potent and specific agonist for morphine (mu) receptors
7. Sequence and expression of the rat prodynorphin gene
8. Kappa opiate receptor multiplicity: Evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype
9. Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys
10. The proenkephalin A fragment, peptide E: Central processing and CNS activity in vivo
11. Regulation of mu-opioid receptor mRNA in rat globus pallidus: Effects of enkephalin increases induced by short- and long-term haloperidol administration
12. Visualization of multiple opiod-receptor types in rat striamm after specific mesencehalic lesions
13. Dynorphin-containing neurons
14. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients
15. The neostriatal mosaic: Multiple levels of compartmental organization in the basal ganglia
16. Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: In situ hybridization histochemical analysis
17. Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: An in situ hybridization histochemistry and fluorescent retrograde tracing study
18. Opioid effects on activation of neurons in the medial prefrontal cortex
19. Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat
20. Co-localization of mu opioid receptor is greater with dynorphin than enkephalin in rat striatum
21. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease
22. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat
23. Molecular cloning and sequence determination of rat preproenkephaline cDNA: Sensitive probe for studying transcriptional changes in rat tissues
24. Opioid peptide processing and receptor selectivity
25. Marked progressive loss of kappa opioid receptors in Parkinson's disease
26. Delta-opioid receptor gene expression in the mouse forebrain: Localization in cholinergic neurons of the striatum
27. Endogenous opioid systems
28. Mu, delta, and kappa opioid receptor mRNA expression in the rat CNS: An in situ hybridization study
29. Kappa I receptor mRNA distribution in the rat CNS: Comparison to kappa receptor binding and prodynorphin mRNA
30. Mu-Opioid receptor mRNA expression in the rat CNS: Comparison to mu-receptor binding
31. Pharmacological and anatomical evidence of selective mu, delta, and kappa opioid receptor binding in rat brain
32. Delta opioid receptor mRNA distribution in the brain: Comparison to delta receptor binding and proenkephalin mRNA
33. Opioid-receptor mRNA expression in the rat CNS: Anatomical and functional implications
34. 5-hydroxytryptamine-induced excitatory postsynaptic currents in neocortical layer V pyramidal cells: Suppression by mu-opiate receptor activation
35. Autoradiographic localization of mu- and delta-opiate receptors in the forebrain of the rat
36. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists
37. Pathogenesis of dyskinesias in Parkinson's disease
38. Preproenkephalin and preprotachykinin messenger RNA expression in normal human basal ganglia and in Parkinson's disease
39. Levodopa-induced dyskinesia: Review, observations and speculations
40. Substantia nigra opiate receptors on basal ganglia efferents
41. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry
42. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias
43. Effects of steroids on the brain opioid system
44. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
45. Cortical motor overactivation in parkinsonian patients with Ldopa-induced peak-dose dyskinesia
46. Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain
47. Naloxone treatment of L-dopa-induced dyskinesias in Parkinson's disease
48. 14C] 2-deoxy-Dglucose autoradiography
49. Endogenous ligands for kappa-opiate receptors
50. Disappearance of the mu-opiate receptor patches in the rat neostriatum following lesioning of the ipsilateral nigrostriatal dopamine pathway with 1-methyl-4-phenylpyridinium ion (MPP+): Restoration by embryonic nigral dopamine grafts
51. Long-term changes in striatal opioid systems after 6-hydroxydopamine lesion of rat substantia nigra
52. Regulation of kappa opioid receptor mRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA
53. Decrease in delta-opioid receptor density in rat brain after chronic [D-Ala2,D-Leu5]enkephalin treatment
54. Decrease in mu-opioid receptor binding capacity in rat brain after chronic PL017 treatment
55. Striatal opiate mu-receptors are not located on dopamine nerve endings in the rat
56. Chronic cocaine alters brain mu opiod receptors
57. Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain
58. Localization of Mu and delta opioid receptors to anterior cingulate afferents and projection neurons and input/output model of Mu regulation
59. Pathophysiology of parkinsonian motor abnormalities
60. The kappa-opioid receptor: Evidence for the different subtypes
61. Cortex: Areal and laminar structure